MRC IAA 2021 Kings College London

Lead Research Organisation: King's College London
Department Name: Medicine School Office

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The MRC Impact Acceleration Accounts is a key part of MRC's translational research strategy and provides annual awards to institutions to flexibly support a portfolio of translational research projects. MRC IAA is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept and to rapidly de-risk projects across the whole translational pathway so that they become competitive for substantial funding for development.
 
Description Using the Metabolic Microenvironment Chambers to Understand the Function of CAR-T Cells in Ischemic Microenvironments 
Organisation New York University
Country United States 
Sector Academic/University 
PI Contribution Providing expertise and data relating to human CAR-T cell function.
Collaborator Contribution Providing expertise and sharing code for production and anlysis of specific novel culture systems. Training of my PhD student in the collaborators lab (funded by a MRC training travel grant).
Impact No outputs as of yet.
Start Year 2022
 
Description Improving survival without bronchopulmonary dysplasia, and neurodevelopment in extreme preterm babies: PPI survey 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact An online survey was completed. We wanted to hear from parents who have ever had a baby that was born before 28 weeks of pregnancy on the acceptability of this new treatment.

In the first part of the survey, we wanted to know more about their previous experience in participating in clinical trials (3 questions). We then gathered their opinion on the new treatment (5 questions).

The link to the survey was disseminated through Bliss, a UK based charity for babies born premature or sick. Bliss posted a link to the survey on their Twitter and Facebook page. The survey was also sent to local PPI groups, e.g. BRC PPI group for prematurity, St. Thomas' NICU PPI group, and Ickle Pickles Charity. We received in total more than 300 responses. Of these 207 were completed responses. There was significant support for the proposed work:
1. 92% were happy with the treatment approach.
2. 74% were not worried about the treatment side effects.
3. 76% would have agreed to participate in a clinical trial on this treatment if approached. 21% were undecided and only 3% did not want to partcipate.
Additionally several families volunteered to be part of a future Trial Steering Group.
The survey is now closed. The results of the survey will form part of the grant application to the planned MRC DPFS grant application and may help us demonstarte to funders that this research is important.
Year(s) Of Engagement Activity 2023
URL https://qualtrics.kcl.ac.uk/jfe/form/SV_71ea854TzjI0mCa